“Election-proof… Pandemic-proof… Crash-proof… This tiny tech stock is the rare…TRIPLE THREAT”
That’s the teaser headline from the ads I got over the weekend about Dave Lashmet’s favorite COVID-19 testing stock, a pick that he’s apparently making for his Stansberry Venture Technology newsletter… and Stansberry has a massive reach, and it’s a very expensive service (currently “on sale” for $2,500, no refunds).
So what’s the story? This headline from the order form sums it up:
“This is your ONE chance to get in ahead of a potential 565% whirlwind gain from the small American company that could announce its game-changing COVID-19 test any day now.”
We’ve seen quite a few teaser pitches from Dave Lashmet about biotech and pharma stocks over the past few months — he was teasing Biogen (BIIB) earlier this year for its controversial on again, off again Alzheimer’s Drug, and that one just took a massive punch to the face, and more recently he’s been talking up the potential of Rhythm’s (RYTM) obesity drug, which is coming very close to its first FDA decision date. Both interesting stories, no life-changing wealth just yet — his big winners this year, he says, were some of the vaccine hype stories, like Inovio (INO), that soared in the wake of COVID, and it sounds like he was at least wise enough to take some profits on those.
So what’s next? From the ad:
“While most the world is focused on COVID vaccines, the impact of this company’s critical biotechnology is flying completely under the radar… for now.
“But for those paying attention… AND acting quickly… you could see a potential windfall profit of 565% or more in just a matter of months.”
What other clues do we get about this company?
“This is a small, American, biotechnology company with a proven track record of success, that’s working to help our country overcome the threat of COVID-19 and keep ALL of us safer from the virus.
“And management has publicly stated that they’re going to start doing it before the end of the year – right now in Q4, to be more specific.
“That means they could announce government approval and start the sales of their critical technology ANY day now. In fact, depending on when someone’s watching this interview, they may already have.”
We’re told that it’s “apolitical” — that both President-Elect Biden and President Trump are big supporters of the technology, and agree that it needs to ramp up. That’s just a reference to the fact that both men — and indeed, pretty much everybody else in the country — agree that there has to be a dramatic increase in testing before we can stop the spread of the coronavirus. Makes sense — after all, if you don’t know you’ve got it it’s easy to spread it, and even a small decrease in the number of infected people who realize they